have thus far been disappointing. Adjunctive rifampicin remains standard therapy for S aureus prosthetic valve endocarditis and prosthetic joint infections; however, US treatment guidelines for meticillin-resistant S aureus infections advocate against its addition for S aureus bacteraemia or native valve endocarditis in adults, 6 and UK guidelines avoid making a recommendation altogether. 7 The result: heterogeneous practice patterns 8 and equipoise inviting the potential for a well designed clinical trial to confuse the issue with facts. In ARREST, 758 adults with S aureus bacteraemia were randomly assigned to 2 weeks of treatment with either rifampicin (600 mg or 900 mg per day; oral or intravenous) or placebo, in addition to standard antibiotic therapy. The primary outcome was time to bacteriological treatment failure or disease recurrence, or death (all-cause) from randomisation to 12 weeks. After 12 weeks, no significant difference in mortality or bacteriological failure was noted between the rifampicin-treated and placebo-treated groups (17% vs 18%; absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81), but patients treated with rifampicin had more adverse events than those who received placebo (63 to provide evidence of the use of rifampicin in these conditions. Nonetheless, the study provides a definitive result: clinicians should not use rifampicin for S aureus bacteraemia treatment in the absence of indwelling prosthetic material.
Before ARREST, only one adequately powered randomised trial had been completed in patients with S aureus bacteraemia: an industry-sponsored study comparing daptomycin with standard therapy.
9 Clinicians now have additional evidence to answer two S aureus bacteraemia antibiotic therapy questions: daptomycin is not inferior to standard antibiotic therapy, and adjunctive rifampicin does not improve outcomes. However, a daunting list of treatment-related questions remains. Would other antibiotic combinations fare better? What about monotherapy? How long is long enough to treat S aureus bacteraemia? Is an oral stepdown therapy for S aureus bacteraemia ever appropriate?
Trialists face a more fundamental question: how can clinical trials in S aureus bacteraemia be completed? In general, clinical trials are complex; clinical trials in S aureus bacteraemia can verge on Sisyphean. ARREST was an enormous undertaking, requiring prolonged enrolment and an eventual change in study design to adapt to a smaller sample size than was initially planned. At present, a handful of other investigator-initiated trials are ongoing (table) . One study tests a treatment algorithm to establish the antibiotic duration for S aureus bacteraemia (NCT01191840). A second examines the role of combination therapy with a β-lactam antibiotic for meticillin-resistant S aureus bacteraemia (CAMERA-2, NCT02365493). Most challenging are registration trials seeking antibiotic licensure for S aureus bacteraemia. Several novel agents are currently undergoing phase 2 (CF-301, NCT03163446) or phase 3 trials (telavancin, NCT02208063; ceftobiprole NCT03138733) for S aureus bacteraemia. These trials will provide much needed data for clinicians managing these challenging infections. However, the pace of completion for S aureus bacteraemia trials has been outstripped by the urgent clinical need for these data. Outcomes for patients with S aureus bacteraemia remain poor; in ARREST, 12-week Rifampicin for Staphylococcus aureus bacteraemia: give it ARREST
